AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.
This 3-minute education provides a summary of just presented scientific data, recorded during the AHA 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.
- Our reporting is based on the information provided at the AHA 2017 congress -The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- AHA 2017Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy
David H. Birnie, MD